2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD3

CD3

Cluster of differentiation 3

CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR, CD3-zeta, and the other CD3 molecules together constitute the TCR complex.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991183
    SAR-442257
    		Inhibitor ≥99.0%
    SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells.
    SAR-442257
  • HY-P99914
    Emfizatamab
    		Activator
    Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia.
    Emfizatamab
  • HY-P5453
    CFP10 (71–85)
    		99.17%
    CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ T cells from persons expressing multiple MHC class II and class I molecules)
    CFP10 (71–85)
  • HY-P991089
    GEN-1044
    		Inhibitor 98.83%
    GEN-1044 is a bispecific CD3 and oncofetal antigen 5T4 antibody. GEN-1044 shows immunomodulating and antineoplastic activities.
    GEN-1044
  • HY-P991088
    HPN536
    		Inhibitor 99.00%
    HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on T cells, and to serum albumin. HPN536 specifically redirects T cells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation.
    HPN536
  • HY-P990903
    Avitotamig
    		Inhibitor
    HY-P990903 is an CD3E/CD33-targeting [H-γ1 _ L-κ-scFv heavy -κ]-dimer type bispecific antibody.
    Avitotamig
  • HY-P991034
    Trevotamig
    		Inhibitor
    HY-P991034 is an EPCAM/CD3E-targeting H-γ1_L-κ-scFvhl dimer type bispecific antibody.
    Trevotamig
  • HY-P991163
    Tixentamig
    		Inhibitor
    Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers.
    Tixentamig
  • HY-P99147
    Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6)
    		Inhibitor
    Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) is an Armenian Hamster-derived IgG antibody inhibitor, targeting to mouse TCR V gamma 2. Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) reacts with an epitope on the delta chain of the mouse Vγ2 TCR (V gamma 2 T cell receptor). Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) can deplete γδ T cell. Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6) can be used for the researches of infection and immunology, such as herpes simplex virus-1 (HSV-1) infection.
    Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6)
  • HY-P990955
    Ebribafusp alfa
    		Inhibitor
    HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Ebribafusp alfa
  • HY-P990928
    Mipletamig
    		Inhibitor
    HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody.
    Mipletamig
  • HY-P990953
    Zubotamig
    		Inhibitor
    HY-P990953 is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody.
    Zubotamig
  • HY-P990969
    Amtabafusp alfa
    		Inhibitor
    HY-P990969 is an CD3E/CD4-targeting IgG1 λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992).
    Amtabafusp alfa
  • HY-P991706
    Nelvutamig
    		Inhibitor
    Nelvutamig is a humanized immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) antibody targeting ENPP3/CD203c and CD3E. The corresponding isotype control is: Human immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3).
    Nelvutamig
  • HY-P991172
    JNJ-70218902
    JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003).
    JNJ-70218902
  • HY-P991681
    Emaretamig
    		Inhibitor
    Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research.
    Emaretamig
  • HY-P991463
    MS133
    		Inhibitor
    MS133 is a human bispecific antibody (bsAb) targeting CD133/PROM1 & CD3E. MS133 can be used in colon cancer research.
    MS133
  • HY-N10446
    Maydispenoid B
    Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation.
    Maydispenoid B
  • HY-P991102
    Anti-MUC17 Antibody
    		Inhibitor
    Anti-MUC17 Antibody is a human antibody expressed in CHO cells, targeting MUC17. Anti-MUC17 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-MUC17 Antibody
  • HY-P991671
    Anafiltamig
    		Inhibitor
    Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research.
    Anafiltamig
Cat. No. Product Name / Synonyms Application Reactivity